HOUSTON — Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University of Texas MD Anderson Cancer Center with proposed guidelines for systematically dealing with the toxicities of these drugs. Their work, published today in Nature Reviews Clinical Oncology, confronts the two main side effects of chimeric antigen receptor T-cells, known as CAR […]
